<DOC>
	<DOCNO>NCT00496132</DOCNO>
	<brief_summary>This open-label , multicenter , Phase I/II study safety escalate dos single-agent PRO131921 patient chronic lymphocytic leukemia ( CLL ) relapse refractory treatment purine nucleoside analogue-containing regimen . The trial enroll two phase : Phase I dose-escalation portion Phase II expand treatment cohort , enrollment additional patient order expand safety experience collect preliminary anti-leukemia activity data .</brief_summary>
	<brief_title>A Trial Safety Escalating Doses PRO131921 Patients With Relapsed Refractory Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Documented history histologically confirm Bcell CLL Relapsed refractory CLL history prior treatment purine nucleoside analoguecontaining regimen Eligible treatment CLL base criterion adapt National Cancer InstituteWorking Group ( NCIWG ) Response Criteria CLL For patient reproductive potential ( male female ) , use reliable mean contraception For female childbearing potential , negative serum pregnancy test Prior use antiCD20 monoclonal antibody therapy ( rituximab ) Prior use nonCD20 target monoclonal antibody therapy within 6 month enrollment Current recent CLL treatment History severe allergic anaphylactic reaction human , humanize , chimeric , murine monoclonal antibody Evidence acute/active autoimmune hemolytic anemia autoimmune complication CLL Use hematopoietic growth factor RBC and/or platelet transfusion Evidence significant uncontrolled concomitant disease , cardiovascular disease , nervous system , pulmonary , renal , hepatic , endocrine , gastrointestinal disorder Evidence myelodysplasia myelodysplastic change bone marrow examination History cancer CLL ) Known active bacterial , viral , fungal , mycobacterial , infection major episode infection require hospitalization treatment IV antibiotic oral antibiotic A major episode infection require hospitalization treatment IV antimicrobial within 4 week screen oral antimicrobial within 2 week screen Positive hepatitis B C serology Positive human immunodeficiency virus ( HIV ) serology Active cytomegalovirus ( CMV ) disease antigen polymerase chain reaction test Pregnancy lactation CNS leukemia Recent major surgery , diagnostic surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>CLL</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Lymph</keyword>
</DOC>